Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

AstraZeneca's heart drug Brilinta fails in trial

Drug group said blood-thinning treatment missed targets for reducing repeat stroke and heart attacks
AstraZeneca's heart drug Brilinta fails in trial
Fewer people who took AstraZeneca's drug in the trial had a recurrent stroke, but not enough to hit targets

AstraZeneca PLC (LON:AZN) said stroke treatment Brilinta was not as effective as expected in trials, hitting hopes that it would be a flagship new drug.

AstraZeneca said a study of Brilinta/Brilique (ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA), had shown the drug had not met its primary efficacy endpoint of preventing repeat attacks within 90 days.

Fewer people who took AstraZeneca's drug in the trial had a recurrent stroke, heart attack or died than those on aspirin, but the difference was not statistically significant.

AstraZeneca's executive vice-president of global medicine development and chief medical officer, Sean Bohen, said: "We will present the full analysis of the trial results, including  subgroups, at a forthcoming stroke congress and will engage with regulatory agencies on the interpretation of the data."

The so-called Socrates trial evaluated the efficacy and safety of 90-day treatment with Brilinta/Brilique versus aspirin for the prevention of major vascular events in patients over 40 years-old with an acute ischaemic stroke.

Shares in AstraZeneca fell 3.5p to 3911.5p.

 

 

 

 

 

 

Phil-Waller.jpg


Register here to be notified of future AZN Company articles
View full AZN profile

AstraZeneca Timeline

Article
November 29 2016

Related Articles

Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln
cancer cells
January 24 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
Vaxil at the vanguard of immuno-oncology
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.